Ipamorelin Peptide Overview

Ipamorelin is a synthetic growth hormone–releasing peptide (GHRP) developed as a selective agonist of the growth hormone secretagogue receptor (GHSR, also called the ghrelin receptor). In research settings, it’s primarily studied for its ability to stimulate pulsatile growth hormone (GH) secretion with minimal stimulation of ACTH/cortisol compared with earlier GHRPs in preclinical testing. (PubMed)

Endocrine Effects and Research Findings

Selective stimulation of growth hormone release

Ipamorelin is widely described in the scientific literature as a GH secretagogue with high selectivity for GH release, showing a profile more similar to GHRH than to some older GHRPs in terms of reduced off-target pituitary–adrenal activation (especially ACTH/cortisol) in the key pharmacology studies. (PubMed)

Human pharmacokinetics / pharmacodynamics (healthy volunteers)

Controlled clinical pharmacology work in healthy volunteers has evaluated ipamorelin using dose-escalation infusion designs and measured both ipamorelin concentrations and GH responses, supporting that ipamorelin can produce dose-related GH elevations in humans under experimental conditions. (PubMed)

(Important context: the strongest published human evidence is largely pharmacology-focused—i.e., GH response—rather than long-term outcomes like body composition.) (PubMed)

Mechanism

Ipamorelin acts through GHSR/ghrelin-receptor signaling to stimulate GH secretion from the pituitary (via hypothalamic–pituitary pathways). In the broader GHSR agonist literature, GH secretagogues are discussed as a class with varying degrees of GH selectivity and differing effects on other hormones. (Wiley Online Library)

Ipamorelin Specifications

From the NIH PubChem compound record:

• CAS Number: 170851-70-4 (PubChem)

• Molecular Formula: C₃₈H₄₉N₉O₅ (PubChem)

• Molecular Weight: 711.9 g/mol (PubChem)

• Peptide type: synthetic peptide GH secretagogue (GHSR agonist) (PubMed)

Important Notice

This summary is provided for scientific and educational purposes. Ipamorelin is commonly handled as a research compound; descriptions and materials should remain consistent with in vitro laboratory research use by qualified professionals and should not be marketed or labeled as a drug, dietary supplement, food, or cosmetic.

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (1998). (PubMed)

2. Gobburu JV, et al. Pharmacokinetic–pharmacodynamic modeling of ipamorelin in healthy volunteers.(1999). (PubMed)

3. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical research context.(Review) (2020). (Wiley Online Library)

4. NIH PubChem. Ipamorelin compound record (CAS, molecular formula, molecular weight). (PubChem)

Complete Disclaimer

This product is sold exclusively for laboratory research purposes under Section 351 of the Public Health Service Act. It is not intended for human or veterinary use, nor for diagnostic, therapeutic, or cosmetic applications. Purchaser certifies they are properly licensed and equipped to handle research compounds in compliance with all local, state, and federal regulations. EaglePeptidesUSA assumes no liability for misuse or unauthorized handling. By purchasing, you affirm this material will not be introduced into interstate commerce or used in food/drug products.